2؉ -calmodulin-activated serine/threonine-specific protein phosphatase that governs multiple aspects of fungal physiology, including cation homeostasis, morphogenesis, antifungal drug susceptibility, and virulence. Growth of Candida albicans planktonic cells is sensitive to the calcineurin inhibitors FK506 and cyclosporine A (CsA) in combination with the azole antifungal fluconazole. This drug synergism is attributable to two effects: first, calcineurin inhibitors render fluconazole fungicidal rather than simply fungistatic, and second, membrane perturbation by azole inhibition of ergosterol biosynthesis increases intracellular calcineurin inhibitor concentrations. C. albicans cells in biofilms are up to 1,000-fold more resistant to fluconazole than planktonic cells. In both in vitro experiments and in an in vivo rat catheter model, C. albicans cells in biofilms were resistant to individually delivered fluconazole or calcineurin inhibitors but exquisitely sensitive to the combination of FK506-fluconazole or CsA-fluconazole. C. albicans strains lacking FKBP12 or expressing a dominant FK506-resistant calcineurin mutant subunit (Cnb1-1) formed biofilms that were resistant to FK506-fluconazole but susceptible to CsA-fluconazole, demonstrating that drug synergism is mediated via direct calcineurin inhibition. These findings reveal that calcineurin contributes to fluconazole resistance of biofilms and provide evidence that synergistic drug combinations may prove efficacious as novel therapeutic interventions to treat or prevent biofilms.
The dimorphic fungus Candida albicans is a commensal of the human oral, gastrointestinal, vaginal, cutaneous, and mucosal surfaces. In immunocompetent as well as immunocompromised individuals, C. albicans causes cutaneous or subcutaneous infections such as vaginitis or oral thrush or infections of the nails and skin. In patients receiving broad-spectrum antibiotics or undergoing cancer chemotherapy, C. albicans can enter the bloodstream to cause serious systemic invasive disease (6, 38) . Due to the difficulty in identifying antifungal targets unique to fungi that are not shared with the human host, only a restricted number of antifungal agents have been widely used for treating C. albicans systemic infections (12, 32) . One such target unique to fungi is the sterol cell membrane component ergosterol.
Fluconazole is a member of the azole class of drugs that target an essential enzyme (Erg11; lanosterol 14␣-demethylase) in the ergosterol biosynthetic pathway (36, 37) . Fluconazole is the most commonly used antifungal agent for prevention and treatment of candidiasis. However, prolonged use of fluconazole in recent years has contributed to the development of drug resistance in C. albicans and other species. One selective pressure contributing to the emergence of drug resistance is the fungistatic rather than fungicidal nature of fluconazole action.
Difficulty in the treatment of C. albicans infections is compounded by the fact that C. albicans biofilm cells are resistant to many major classes of antifungal drugs, including azoles. Biofilm resistance to fluconazole has been attributed to a compromise in C. albicans cell membrane integrity caused by reduced sterols (16, 20) . A recent report also demonstrated that cell wall ␤-1,3 glucan levels contribute to biofilm resistance to fluconazole (22) . Emerging resistance in both planktonic as well as biofilm-associated C. albicans isolates poses challenges to the successful use of fluconazole as a single-drug treatment option (16, 24) . However, a caveat for two-drug combination strategies (where one drug is fluconazole) is that some drug combinations can have disparate effects on C. albicans planktonic and biofilm cells. Fluconazole in combination with amphotericin B (AmB) has a synergistic effect on C. albicans planktonic cells but does not alter AmB activity against biofilms (1, 2, 24). Also, fluconazole and caspofungin have an antagonistic effect against biofilms but not with planktonic cells (2) . Given these concerns, identifying antifungal drugs that are synergistic with fluconazole for the treatment of both drug-resistant C. albicans planktonic cells and biofilms is of importance. Recent studies have documented that the calcineurin inhibitors cyclosporine A (CsA) and tacrolimus (FK506) are dramatically synergistic with azoles, resulting in potent fungicidal activity (8, 11, 18, 23, 30, 35) . Calcineurin is a Ca 2ϩ -calmodulin-activated phosphatase that governs fungal physiology, including regulation of cell cycle progression, morphogenesis, mating and cytokinesis, recovery from pheromone arrest, cation homeostasis, cell wall biosynthesis, antifungal drug resistance, and virulence (13, 19, 27, 29, 34, 35, 39) . Mutant strains lacking calcineurin are markedly hypersensitive to azoles (11, 32) . When combined with fluconazole, calcineurin inhibitors render azole drugs fungicidal rather than fungistatic. Also, fluconazole-mediated membrane perturbation (due to inhibition of ergosterol biosynthesis) increases calcineurin inhibitor intracellular concentrations (11) . These results stimulated an interest in determining whether synergism of fluconazole-calcineurin inhibitor drug combinations could be extended to C. albicans biofilms.
We found that both in vitro and in an in vivo rat catheter model, C. albicans calcineurin mutants formed biofilms comparable to those of the wild-type strain. Fluconazole or calcineurin inhibitors delivered individually had no effects on wild-type biofilms. On the other hand, biofilms were exquisitely sensitive to either FK506-fluconazole or CsA-fluconazole combinations. C. albicans strains lacking the FK506 binding protein (FKBP12) or expressing a dominant FK506-resistant calcineurin mutant subunit (Cnb1-1) formed biofilms that were resistant to FK506-fluconazole but susceptible to CsA-fluconazole. These results document that drug synergism is mediated via direct inhibition of C. albicans calcineurin. In summary, these studies reveal that calcineurin contributes to fluconazole resistance of biofilms, and they identify a synergistic drug combination for treating or preventing biofilms.
MATERIALS AND METHODS
C. albicans strains. C. albicans strains used in this study were SC5314, K1, and DAY185, C. albicans calcineurin B homozygous mutant cnb1/cnb1 (DAY364) and its complemented strain cnb1/cnb1ϩCNB1 (MCC85), C. albicans zinc finger transcription factor mutant crz1/crz1 (OCC1.1) and its complemented strain crz1/crz1ϩCRZ1 (OCC7), the FK506-resistant calcineurin mutant CNB1-1/ CNB1 (JRB61), and the rbp1/rbp1 C. albicans strain lacking FKBP12 (YAG171). All strains except K1 are congenic with the SC5314 strain background. The strains were routinely maintained and grown in YPD liquid medium (20 g of peptone, 10 g of yeast extract, 20 g of glucose per liter) at 30°C. All strains had normal and comparable growth rates.
Biofilm growth conditions. Two in vitro models were used to assess biofilm growth and drug susceptibility. The first model utilized a 96-well polystyrene plate as a substrate, as previously described (22, 28) . Briefly, cells were grown in YPD overnight at 37°C and resuspended in RPMI buffered with HEPES at a concentration of 10 6 cells/ml based on hemocytometer calculations. An inoculum (100 l) was added to each well of a 96-well flat-bottom plate. After a 24-h incubation at 37°C, the wells were washed with phosphate-buffered saline (PBS) three times to remove any nonadherent cells.
In the second model, biofilms were also grown on silicon elastomer (SE) surfaces as described previously (31) . Briefly, strains were grown overnight in YPD medium at 30°C and diluted to an optical density at 600 nm of 0.5 in Spider medium. The suspension was added to a sterile 12-well or a 48-well plate containing bovine serum (B-9433; Sigma)-treated SE squares (cardiovascular instrument silicone sheets; PR72034-06N). The inoculated plates were incubated at 37°C for 90 min at 150 rpm agitation for the initial adhesion of cells. The squares were washed with PBS, transferred to fresh plates containing fresh Spider medium, and incubated at 37°C for 48 h at 150 rpm agitation to allow biofilm formation.
Quantitative measurement of biofilms. Biofilms were quantified by both dry weight measurements and colorimetrically by a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT; Sigma) reduction assay. For dry weight measurements, the SE squares were weighed prior to biofilm development. After 48 h of biofilm formation, the biofilms were washed gently with sterile PBS and air dried at 37°C for 24 h. The total biomass of each biofilm was calculated by subtracting the weight of the silicone prior to biofilm growth from the weight of the silicone after biofilm growth.
XTT solution (1 mg/ml) was prepared in PBS; menadione solution (0.4 mM; Sigma) was prepared in acetone. The two solutions were added to the wells containing PBS-washed biofilms at a ratio of 5:1 (vol/vol), and the plates were incubated for 3 h at 37°C in the dark. After incubation, the liquid was removed from each well and clarified by centrifugation, and XTT formazan production was measured by determining the absorbance at 492 nm.
In vitro biofilm drug susceptibility. Biofilms were formed in 96-well plates as described above. After 24 h, fresh medium (RPMI/HEPES) and drugs were added to wells. Dilutions of fluconazole (0.25 to 1,000 g/ml), FK506 (0.005 to 300 g/ml), and cyclosporine (1.2 to 300 g/ml) were examined alone and in combination in a checkerboard format. The ranges of concentrations of the drugs used included the standard doses given to humans. After 24 h of incubation at 37°C, biofilms were washed twice with PBS. Measurement of biofilm cell metabolic activity using the XTT reduction assay was performed as previously described (22, 28) . Briefly, 90 l of XTT (1 mg/ml) and 10 l phenazine methosulfate (320 g/ml) were added to each well, and the plate was incubated at 37°C for 2 h. Absorbance at 492 nm was measured using an automated plate reader. Assays were performed in triplicate. We determined the drug concentration associated with a 50% reduction in optical density compared to the no-drug control wells (EC 50 ). The fractional inhibitory concentration (FIC) was then calculated as follows: [(EC 50 of drug A in combination)/(EC 50 of drug A alone)] ϩ [(EC 50 of drug B in combination)/(EC 50 of drug B alone)]. Values of Յ0.5 revealed synergy, those of Ͼ0.5 but Ͻ2 indicated no interaction, and those of Ͼ2 were antagonistic (22) .
Under many conditions, drug susceptibility testing was also performed for cells in biofilms grown on SE. Mature biofilms were washed gently with sterile PBS and transferred to fresh 12-well plates containing Spider medium supplemented with the appropriate concentration(s) of a single drug or a combination of two drugs. The biofilms were further incubated for 48 h, and metabolic activities of biofilms were measured by the XTT reduction assay. The MIC was defined as the antifungal concentration that caused a 50% reduction in metabolic activity of a C. albicans biofilm compared with the control (incubated in the absence of drug). The drugs used were fluconazole (Sigma, St. Louis, MO), FK506 (Prograf; Astellas Pharma US, Inc., Deerfield, IL), and CsA (Alexis Corporation, San Diego, CA).
In vivo biofilm drug susceptibility. A rat central venous catheter infection model was selected for in vivo biofilm studies (1, 21) . Specific-pathogen-free Sprague-Dawley rats weighing ϳ400 g were used (Harlan Sprague-Dawley, Indianapolis, IN). A heparinized (100 U/ml) polyethylene catheter was surgically inserted into the external jugular vein and advanced to a site above the right atrium (2-cm length). The catheter was secured to the vein, and the proximal end was tunneled subcutaneously to the midscapular space and externalized through the skin. The catheters were implanted 24 h prior to inoculation. Infection was achieved by intraluminal instillation of 500 l C. albicans strain K1 (10 6 cells/ml). After 4 h, the catheters were flushed and maintained with heparinized 0.15 M NaCl for 24 h to allow for biofilm formation. Catheters were then treated with fluconazole (125 g/ml), FK506 (20 g/ml), or a combination for 16 h. These concentrations were picked based on their efficacies in the in vitro drug combination experiments. For controls, animals were treated with saline. Two animals were used per time and treatment point. At the end of the observation period, the catheters were removed and processed for electron microscopy, as described below.
Confocal microscopy. Biofilms were stained with 25 g/ml concanavalin A-Alexa Fluor 594 conjugate (C-11253; Molecular Probes, Eugene, OR) for 1 h in the dark at 37°C. Confocal scanning laser microscopy was performed with a Zeiss LSM 510 upright confocal microscope using a Zeiss Achroplan 40ϫ, 0.8-W objective. Concanavalin A conjugate staining was observed using a HeNe1 laser with an excitation wavelength of 543 nm. Images were assembled into side and depth views using the Zeiss LSM Image Browser v4.2 software. Artificially colored depth view images indicate cell depth using a color gradient, where cells closest to the SE are represented in blue and the cells farthest away are represented in red.
Scanning electron microscopy. Silicon elastomer squares containing biofilms were introduced without fixation into the environmental scanning electron microscope (Philips XL30 ESEM TMP; FEI Company, Hillsboro, OR; NSF award DBI-0098534). The ESEM allows examination of any specimen, wet or dry, in situ and close to its natural state. Samples were examined at 10 kV, 5 torr pressure, and at a temperature of 3°C. The samples remained hydrated throughout the process. Catheter segments were processed for scanning electron microscopy as previously described (1). After overnight fixation (4% formaldehyde, 1% glutaraldehyde in PBS), catheter segments were washed for 5 min in PBS and placed in 1% osmium tetroxide for 30 min. Drying was accomplished using a series of alcohol washes followed by critical point drying. Catheter segments were mounted and gold coated. Images were obtained with a scanning electron microscope (JEOL JSM-6100) in the high-vacuum mode at 10 kV. The images were assembled using Adobe Photoshop 7.0.1.
RESULTS
Calcineurin is not required for C. albicans biofilm formation in vitro or in vivo. Calcineurin governs several important physiological properties in C. albicans, including C. albicans survival in serum, virulence in a murine model of systemic candidiasis, and resistance to azole antifungals (7, 9, 11, 23, 32) . Azole tolerance is mediated in part via the calcineurin target Crz1 (15, 25, 33) . Although calcineurin does not control C. albicans properties of adhesion or filamentation (3, 4, 9) , two properties important for biofilm formation, given its broad physiological roles we hypothesized that calcineurin might be involved in C. albicans biofilm formation. To test this, C. albicans cnb1/cnb1 (lacking calcineurin B) and crz1/crz1 (lacking a transcription factor controlled by calcineurin) mutants were first used to develop biofilms in vitro on silicone elastomer squares. After 48 h of development at 37°C, biofilms were quantitated by two independent methods, dry weight measurements and XTT assays. No significant difference (P Ͼ 0.3) was observed between the biofilms formed by the C. albicans wildtype strain and the C. albicans calcineurin or crz1 mutant strains (Fig. 1) . Also, as expected, the complemented strains of the C. albicans calcineurin and the crz1 mutants developed biofilms as robustly as the C. albicans wild-type strain (Fig. 1) .
The ability of the C. albicans cnb1/cnb1 mutant to form a biofilm in vivo was examined using the venous catheter animal model (Fig. 2) . Similar to the wild-type strain, cnb1/cnb1 formed a mature biofilm 24 h after inoculation. Scanning electron microscopy imaging demonstrated similar biofilm architecture between the wild-type and mutant strains. Both biofilms were of comparable thickness and consisted of a combination of adherent yeast and hyphae surrounded by matrix and host components.
Calcineurin is involved in C. albicans biofilm resistance to fluconazole. C. albicans cnb1/cnb1 and crz1/crz1 mutant strains are known to be hypersensitive to fluconazole compared to wild-type cells under planktonic growth conditions (23, 25, 30, 33) . The fact that these mutants formed morphologically wildtype biofilms allowed us to test if these strains were also azole hypersensitive under biofilm conditions. Mature biofilms were treated for 48 h with a range of fluconazole concentrations (0.25 g/ml to 1,024 g/ml). The MIC 50 of fluconazole for biofilm cells was calculated based on results from the XTT assay. C. albicans cnb1/cnb1 biofilm cells were at least 15-fold more sensitive to fluconazole than wild-type biofilms, and those formed by the C. albicans crz1/crz1 mutant were at least 8-fold more sensitive ( Table 1) . Complementation of the cnb1 and crz1 mutations with the wild-type gene restored wild-type levels of azole resistance in biofilms (Table 1) . These results are complementary to earlier reports that, under planktonic conditions, crz1/crz1 mutants are less fluconazole hypersensi-
Calcineurin is not required for C. albicans biofilm formation. Biofilms were grown as described in Materials and Methods, metabolic activity was measured by XTT assay (A), and biomass was measured based on dry weight (B). Assays were performed in triplicate. Biofilms were not significantly different from each other (P Ͼ 0.3, analysis of variance).
FIG. 2. The C. albicans calcineurin mutant forms a biofilm in vivo.
C. albicans wild type and cnb1/cnb1 were instilled in rat venous catheters. The ability to form a biofilm and biofilm architecture were evaluated by scanning election microscopy imaging at 24 h. The top row represents a 50ϫ magnification (bar, 600 m), and the bottom row represents 1,000ϫ magnification (bar, 30 m). Experiments were performed in duplicate. Biofilm thickness and architecture were similar between the two strains. tive than cnb1/cnb1 mutants (but both strains are significantly more sensitive than wild-type C. albicans cells) (15, 25) . C. albicans biofilms are hypersensitive to calcineurin inhibitor-fluconazole combinations. The increased fluconazole susceptibility of the cnb1/cnb1 mutant biofilms indicated that calcineurin may be responsible for the resistance of C. albicans biofilms to fluconazole. This hypothesis was further tested by exposing wild-type C. albicans biofilms to a combination of calcineurin inhibitors and fluconazole. Previous studies demonstrated that C. albicans planktonic cells are hypersensitive to combinations of calcineurin inhibitor (either FK506 or cyclosporine A) and fluconazole (11, 17, 18) . If calcineurin were indeed responsible for mediating fluconazole resistance, then biofilms cells might also exhibit sensitivity to the drug combination.
Measurement of metabolic activity of biofilm cells in an XTT assay revealed that biofilm cells were resistant to CsA (1 to 300 g/ml), FK506 (0.005 to 300 g/ml), or fluconazole (0.25 to 1,024 g/ml) delivered individually ( Table 2) . However, biofilm cells were found to be exquisitely sensitive to either an FK506-fluconazole or CsA-fluconazole combination, with FIC indexes as low as 0.08 and 0.13 for the respective drug combinations, indicating a synergistic interaction ( Table 2) .
In addition to the XTT assays, we performed confocal scanning laser microscopy (CSLM) to examine the architecture of biofilms treated with the FK506-fluconazole combination compared to individual drug treatment. Side and depth biofilm analyses revealed no significant difference between the biofilms formed by the wild-type untreated, fluconazole-treated, or FK506-treated cells (ϳ300 m) (Fig. 3) . However, the biofilms treated with the FK506-fluconazole combination were significantly reduced in thickness by ϳ5-fold to 20% the depth produced by cells under the other conditions (Fig. 3) .
To examine the impact of the FK506-fluconazole combination in vivo, we used a rat venous catheter biofilm model and imaged treated and control biofilms by scanning electron microscopy (Fig. 4) . Addition of fluconazole alone (125 g/ml) or FK506 alone (20 g/ml) had minimal impact on mature wildtype C. albicans biofilms, compared to a saline-treated control. However, imaging of the two-drug combination demonstrated the complete inhibition of the biofilm.
To test if calcineurin is involved in the toxic effect of the FK506-fluconazole combination, two FK506-resistant strains were analyzed: first, a strain lacking the RBP1 gene, whose product is required to bind FK506 and inhibit calcineurin (10, 11) , and second, CNB1-1, a mutant strain that expresses a dominant drug-resistant form of calcineurin B that has reduced affinity for FKBP12-FK506 but wild-type sensitivity to cyclophilin A-CsA (11, 14) . If calcineurin is required for the observed synergistic interaction between FK506 and fluconazole in C. albicans, then both the rbp1/rbp1 and CNB1-1 mutations should confer resistance to the drug combination while continuing to be sensitive to the CsA-fluconazole combination. Indeed, both the rbp1/rbp1 and CNB1-1 strains were completely resistant to the FK506-fluconazole combination (FIC, 2.0) but remained sensitive to the CsA-fluconazole combination (FIC, 0.31 to 0.37), confirming that calcineurin is directly involved in biofilm resistance to fluconazole (Tables 1  and 2 ).
DISCUSSION
Calcineurin is a Ca 2ϩ -calmodulin-dependent protein phosphatase that controls myriad processes in fungi, including cation homeostasis, morphogenesis, virulence traits, and antifungal drug resistance (13, 27, 29, 34) . In C. albicans, calcineurin is required for survival in serum, virulence, and resistance to azole antifungals, in part via its downstream target, Crz1 (7, 9, 11, 15) . Given these broad physiological roles, we tested if calcineurin or Crz1 had any role in C. albicans biofilm formation in vitro and in an in vivo rat catheter model. Dry weight measurements and XTT assays of in vitro biofilms and SEM images of in vivo biofilms revealed that both calcineurin as well as Crz1 were dispensable for biofilm formation in C. albicans. Also, when wild-type biofilms were grown in the presence of the calcineurin inhibitors FK506 (Fig. 2 and 4) or CsA (data not shown), there was no negative effect on biofilm development. These results were not surprising in light of the fact that calcineurin does not control C. albicans adhesion or filamentation-properties critical for biofilm development (11, 31) .
Although calcineurin mutants and Crz1 were not found to be involved in C. albicans biofilm growth, the biofilms they formed were more susceptible to the azole drug fluconazole ( Table 1) . The sensitivity of calcineurin mutants to fluconazole has been reported previously under planktonic conditions (11, 28, 35) . We have shown here that this phenomenon also applies to the biofilm setting.
To confirm that calcineurin is indeed involved in biofilm resistance to fluconazole, we treated the wild-type biofilm cells with a combination of calcineurin inhibitors and fluconazole. The calcineurin inhibitors CsA and FK506 are immunosuppressive drugs that exhibit potentials as antifungal agents, either singly or in combination with other antifungal agents, such as azoles (8, 18, 21) . Both CsA-fluconazole and FK506-fluconazole combinations were highly synergistic in action against C. albicans wild-type biofilms both in vitro and in vivo ( Table 2 ; Fig. 3 and 4) , and calcineurin and FKBP12 were the exclusive targets of the FK506-fluconazole combination (Table 2 ).
In C. albicans planktonic cells, fluconazole treatment significantly reduces levels of ergosterol within the cell, leading to cell membrane perturbation (11) . The resulting alteration in the permeability of the plasma membrane allows increased concentrations of calcineurin inhibitors to penetrate the cell, resulting in cell death. We speculate that fluconazole similarly decreases the sterol concentration in biofilms and, thereby, its combination with calcineurin inhibitors renders the combination fungicidal.
Inhibition of C. albicans biofilms by this combination is significant in light of the studies that have reported on the failure of various antifungal drug combinations against biofilms. These drug-resistant biofilms, especially those that form on indwelling medical devices, are essentially untreatable, thereby making removal of the colonized device the only treatment   FIG. 4 . Impact of fluconazole and FK506 alone and in combination as lock therapy against C. albicans biofilm cells in an in vivo catheter model. The biofilms were grown for 24 h followed by intraluminal drug treatment for 16 h. Following compound exposure, the catheters were removed for SEM processing. For each of the four panels, the top row represents a 50ϫ magnification (bar, 600 m) and the bottom row represents 1,000ϫ magnification (bar, 30 m). Panel columns: no treatment, images from a control biofilm treated with saline; fluconazole, images after a 125-g/ml fluconazole exposure; FK506, images from catheters exposed to FK506 at 20 g/ml; fluconazole ϩ FK506, images from a combination of fluconazole and FK506 at 125 g/ml and 20 g/ml, respectively.
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at Univ of Wisconsin -Mad on February 28, 2008 aac.asm.org option available. Calcineurin inhibitor-fluconazole combinations could prove an effective antifungal regimen to prevent or eradicate these biofilm-associated cells and may thus allow for longer retention of implanted devices. The mechanism of C. albicans biofilm resistance to fluconazole is considered multifactorial, encompassing contributions of cell density, impermeability of drugs through the extracellular matrix, activation of multidrug efflux pumps, increases in cellular ␤-1,3 glucan levels, and decreases in sterol levels (5, 20, 22, 26) . Our study reveals that calcineurin is an important component in mediating fluconazole resistance in biofilms of C. albicans. We also suggest that calcineurin inhibitor-fluconazole drug combinations may prove to be a novel and effective therapeutic option.
Cyclosporine is already being broadly marketed for dry eye syndrome and could be readily applied for other indications in ophthalmology. FK506 analogs, such as pimecrolimus, that have less-penetrating properties than FK506 could be readily applied for topical fungal infections in conjunction with existing topical or systemic antifungals (35) . Other settings might include troches for oropharyngeal candidiasis or impregnated catheters with these or other inhibitors.
